Applied Genetic Technologies Corp (AGTC) is Reiterated by Stifel to Buy, Lowers Price Target to $ 24

Applied Genetic Technologies Corp (AGTC) was Reiterated by Stifel to “Buy” while Lowering the Price Target of the company shares to $ 24 from a previous price target of $29 . Stifel advised their investors in a research report released on Sep 13, 2016.

Many Wall Street Analysts have commented on Applied Genetic Technologies Corp. Shares were Reiterated by Wedbush on Sep 13, 2016 to “Outperform” and Lowered the Price Target to $ 20 from a previous price target of $36 .

On the company’s financial health, Applied Genetic Technologies Corp reported $0.15 EPS for the quarter, beating the analyst consensus estimate by $ 0.07 according to the earnings call on Sep 12, 2016. Analyst had a consensus of $0.08. The company had revenue of $12.10 million for the quarter, compared to analysts expectations of $13.09 million. The company’s revenue was up 1604.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.48 EPS.

Applied Genetic Technologies Corp opened for trading at $12.69 and hit $13.33 on the upside on Monday, eventually ending the session at $13.19, with a gain of 6.63% or 0.82 points. The heightened volatility saw the trading volume jump to 172,813 shares. Company has a market cap of $238 M.

In a different news, on Jan 26, 2015, Daniel L Menichella (V.P. & Chief Business Officer) sold 1,996 shares at $24.90 per share price.

Applied Genetic Technologies Corp is a United States-based clinical stage biotechnology company. The Company develops gene therapy products for the treatment of inherited and acquired diseases. Its products are used to treat Alpha One Antitrypsin Deficiency (Alpha-1) a respiratory disease caused by deficiencies in the tissue protective protein alpha one antitrypsin; and Lebers congenital amaurosis an inherited condition causing early blindness. Its products also used to treat X-linked retinoschisis an inherited form of retinal degeneration affecting young males with poor vision either in infancy or at school age; and achromatopsia an inherited condition that is associated with color blindness visual acuity loss and extreme light sensitivity resulting in daytime blindness.

Applied Genetic Technologies Corp

Leave a Reply

Applied Genetic Technologies Corp - Is it time to Sell?

Top Brokerage Firms are advising their investors on Applied Genetic Technologies Corp. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.